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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic, autoimmune disease 
with unknown etiology. In this disease, demyelination 
and axonal damage to CNS neurons cause physical and 
mental disabilities, and mostly affects young people and 
business community. This disease incurs huge costs that 
health system has to pay. Despite medical advances in 
recent years there is still no definite cure for this disease.  
According to the world health organization, MS 
incidence is growing all around the world, and its annual 
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Background: The World Health Organization states that the prevalence of MS is increasing. Due to the growth in the 
number of people with MS, and because this disease involves the working youth community and is  a debilitating 
illness and also there is no exact treatment for it, thus, eliminating the risk factors of this disease through new and 
cost-effective methods is essential. It has been proven that vitamin D3 performs an active role in the immune system. 
The role of vitamin D on the immune system is to increase phagocytic monocytes and to reduce secretion of TNF-α, 
IL-12 and PGE2 by monocytes. Vitamin D3 serum Levels in MS patients have had conflicting results in different 
studies. The Purpose of this study was to compare serum levels of vitamin D3 in patients with MS and healthy 
subjects, and also to examine the relationship between vitamin D3 serum levels and the severity and the number of 
attacks in MS patients during a year. 
Methods: In this case-control study, 60 patients with MS were selected for case group and 60 healthy people, 
matched to the case group in terms of sex and living conditions, were chosen as the control group. Serum samples 
were taken for laboratory examination of vitamin D3 serum levels. Then, the collected data was analyzed by SPSS.16.  
Results: Of samples 25% were male, and the rest of them were female. The mean age of the control group was 20 ± 4 
years and that of case group was 19.3 ± 2.8 years. The prevalence of deficiency and inadequate levels of vitamin D3 
was higher in MS patients than healthy people in the control group. Deficiency of vitamin D3 was higher among 
women in both groups. In MS group, prevalence of inadequate levels of vitamin D3 was 35.6% among women, while 
it was 13.3% among men. But in the control group, prevalence of inadequate levels of vitamin D3 was higher among 
men (40% versus 13.3%). The incidence of recurrence was 13.3%, 11.1% and 11.1% among MS patients with normal 
levels of vitamin D3, MS patients with inadequate levels of vitamin D3, and MS patients with deficiency of Vitamin 
D3, respectively, but the difference between them was not statistically significant.  
Conclusions: Results showed that the serum levels of vitamin D3 are low in Ardabil province and even lower among 
women; and particularly in MS patients compared to healthy people. There was no significant relation between the 
number of attacks per year and serum levels of vitamin D3.  
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incidence is estimated 3.6 and 2 persons per 100 people, 
in women and men respectively. The higher incidence 
rate of the disease in women continues to grow day by 
day compared to men, as such it is reported that the ratio 
has increased from 1.4 in 1955 to 2.3 in 2000.   
The incidence rate of MS continues to be higher in 
women than man, and it even goes up day by day, as such 
the ratio has increased from 1.4 in 1955 to 2.3 in 2000. 
According to the MS Society's statistics, currently, 30 
thousand patients are suffering from the disease in Iran. 
Despite medical advances, MS is still the most common 
cause that cripples young people. Due to high growth and 
taking into account the fact that there is no definite cure 
for the disease, the prevention of the disease with new 
and economical ways seems necessary. 
The disease is more commonly known as relapsing and 
recovery attacks. Several risk factors have been identified 
for MS that genetic is at one end of the spectrum and 
environmental factors are at the other. To mention some 
environmental factors we can refer to getting infected 
with EBV, smoking and low levels of vitamin D3. As it is 
proven, vitamin D3 serves an active role in the immune 
system.
1,2
 
Because of the difference in the levels of vitamin D3 in 
patients with multiple sclerosis, this study aimed to 
measure serum levels of vitamin D3 in patients with 
multiple sclerosis compared with healthy individuals. 
METHODS 
In this case-control study, 60 patients diagnosed with 
multiple sclerosis were chosen as the case group, and 60 
healthy people were included in this study as the control 
group. The individuals in both groups were similar in 
terms of sex, age, living condition such as residential area 
and exposure to sunlight. Blood serum samples were 
taken from everybody to determine the level of vitamin 
D3 and information of all persons was obtained and 
registered in the checklist. The data were analyzed by 
SPSS V.16 using descriptive statistics and statistical 
analysis.  
Exclusion criteria were presence of underlying disease, 
such as chronic renal failure, endocrine disease, receiving 
pulse corticosteroid therapy more than twice a year, 
recent use of steroids (in the past two months), 
consumption of cyclosporine and other drugs, and not 
being treated with vitamin D. The study was conducted 
after getting approval from ethics committee of the 
University and obtaining written consent from the 
patients. 
RESULTS 
Both groups included 15 men (25%) and 45 women (75 
percent). The age range of people in both groups varied 
from 15 to 40. The average age of the control group was 
20 ± 4 years and the average age of case group was 19.3 
± 2.8 years. The prevalence of inadequate levels of 
vitamin D3 deficiency was 75% in patients with MS, and 
55% in the healthy group. There was no significant 
difference between the two groups pertaining to the level 
of vitamin D3 (Table 1). 
Table 1: Frequency distribution of vit. D3 by study 
groups.  
Group 
 
Vit. D3 levels 
MS group Control  
N % N % 
Normal  15 25 27 45 
Inadequate 18 30 12 20 
deficiency 27 45 35 17.5 
Total 60 100 60 100 
In both groups, vitamin D3 deficiency among women 
were more likely than men either with multiple sclerosis 
or healthy. Differently put, 57.8 percent of women and 
6.7 percent of men with MS were deficient in vitamin 
D3; similarly, 46.7 percent of women, and none of the 
men were deficient in vitamin D3 in the healthy group. 
Related to inadequate levels of vitamin D3, 35.6 percent 
of women with MS had insufficient levels of vitamin D, 
while this amount was 13.3 percent among men in the 
group. However, the prevalence of inadequate vitamin 
D3 levels in healthy men was higher than in women (40 
percent vs. 13.3 percent). 
The statistical analysis showed that vitamin D3 levels 
among women and men were significantly different in 
both MS and control groups. In other words, the gender 
had no relation with vitamin D3 levels in the two groups 
(Table 2). 
Table 2: Frequency distribution of vit. D3 by study 
groups and sex.  
Sex 
 
Group 
Male  Female  Total  
N % N % N % 
MS 
Normal 12 80 3 20 15 25 
Inadequate 2 10.1 16 88.9 18 30 
deficiency 1 3.7 26 86.3 27 45 
Control 
Normal 9 33.3 18 66.7 27 45 
Inadequate 6 50 6 50 12 50 
deficiency 0 0 21 100 21 35 
The overall incidence of relapse was 11.7% in patients 
with MS, and 42.9% in MS patients with a deficiency of 
vitamin D3, showing no significant relationship between 
levels of vitamin D3 and MS relapse (Table 3). 
Fattahzadeh Ardalani Gh et al. Int J Adv Med. 2015 Nov;2(4):393-396 
                                                    International Journal of Advances in Medicine | October-December 2015 | Vol 2 | Issue 4    Page 395 
Table 3: Prevalence of relapses in MS patients by vit. 
D3 level.  
Group 
 
Vit. D3 levels 
With 
relapses  
Without 
relapses 
N % N % 
Normal  2 28.6 13 24.5 
Inadequate 2 28.6 16 30.2 
deficiency 3 42.9 24 45.3 
Total 7 11.7 53 88.3 
DISCUSSION 
In this study 25% of patients with MS had normal levels 
of vitamin D3 (80% of men and 66.6% of women) and 30 
percent of them had insufficient levels of vitamin D3 
(13.33 percent of men and 35.55 percent of women), 45% 
of them had vitamin D3 deficiency (6.66 percent of men 
and 57.77 percent of women). 
On the contrary, in the control group 45% of patients had 
normal levels of vitamin D3 (60% men, and 40% of 
women) and 20% of them had inadequate levels of 
vitamin D3 (40% of men and 13.33% of women) and 35 
percent were deficient in vitamin D3 (46.66% of the 
women). No significant relationship was obtained 
between levels of vitamin D3 and developing MS. 
Shah-Beigy and colleagues in a study evaluated the 
serum levels of 25-hydroxyvitamin D in MS patients 
compared with the control group. They found that the 
mean serum level (OH) D 25 in patients with MS was 
19.05% ± 2.4, and in control group was 35.8 ± 8.8. And 
the number of MS patients who lacked vitamin D or had 
inadequate levels of serum vitamin D was 76.7 and 6.7, 
respectively. This study also confirmed the relationship 
between vitamin D and MS, which is consistent with the 
results of our study and the low levels of vitamin D3 in 
patients of our study can be attributed to their less 
exposure to the sun.
3
 
In a study by Munger et al., it was showed that those who 
had higher vitamin D through taking multivitamin 
supplements were significantly less affected by MS. 
Their study indicated vitamin D intake reduced the risk of 
MS to the extent of 40%.
4
 
Hejazi et al., in a study examined dietary intake of 
vitamin D and 25 (OH) D3 serum levels  in MS patients 
and healthy individuals, and revealed the prevalence of 
severe vitamin D deficiency in more than one-third of 
both groups (33% of patients, and 37% of healthy 
people). There was no significant difference between the 
two groups regarding 25 (OH) D serum levels.
5
 
Ponsonby and colleague’s study showed that the 
prevalence of MS had a reversed relationship with the 
amount of sunlight exposure; while the relationship 
between sunlight exposure and MS was even greater than 
the degree of relationship between sunlight and malignant 
melanoma disease.
6
  
On the other hand Soilu-Hanien and colleagues have 
reported no significant difference between MS patients 
and healthy people in terms of 25 (OH) D 3 serum levels 
in the winter season.
7
 
Ozgocmen and colleagues, however, have shown that 
levels of 25 (OH) D 3 were lower in MS patients than 
healthy individuals.
8
 
Kassandra and colleagues’ study found 41% reduction in 
the risk of getting MS as 25 (OH) D 3 serum levels 
increased to the degree of 50 nmol/L in those with light 
complexion. Their finding approves the protective effect 
of vitamin D in MS disease through several mechanisms, 
such as preventing from production of antibodies and 
pro-inflammatory cytokines.
9
 
Furthermore, during the MS patients’ one year follow-up, 
no significant relationship was detected between the 
number of attacks per year and vitamin D3 level. About 
28.6 of those with normal levels of vitamin D3 had 
recurrence over the past year. This rate was 28.6% and 
42.9% in patients with inadequate levels of vitamin D3, 
and vitamin D3 deficiency, respectively. However, this 
difference was not statistically significant. 
Samantha and colleagues in a study investigated the 
prevalence of vitamin D deficiency and bone mass loss in 
patients with MS. Within a 28-week protocol, they 
treated 12 patients, who were in their active stage of MS, 
with calcium (1200 mg daily) and vitamin D3 (700 to 
7000 micrograms per week) supplements. The mean 
serum concentration of vitamin D was 78 nmol/L at the 
beginning that reached to 386 nmol/L at the end of the 
study. Although during this study, the disease's progress 
and activity was not affected, but the number of 
gadolinium-enhancing lesions per patient was reduced to 
a considerable extent.
10
 
Deseilligny and colleagues in a study examined the 
relationship between serum levels of 25-OH-D and the 
incidence rate of relapse in MS patients before and after 
taking vitamin D dietary supplements. In this observation 
study which had no control group, 156 patients with 
relapsing-remitting MS, who had 25-OH-D serum levels 
less than 100 nmol/L, were treated with vitamin D3 
supplements. While treating with supplements, the 
patients’ 25-OH-D levels rose from mean level of 49 
nmol/L in the beginning of the study to 110 nmol/L at the 
end.  Integrating the collected data before and after taking 
supplements showed a strong inverse relationship 
between MS recurrence & 25-OH-D levels (P <0.0001).
11
 
Several studies in Iran and Middle-Eastern countries have 
reported a high prevalence of vitamin D deficiency.
12,13
 In 
the present study, the number of people with vitamin D3 
deficiency or insufficient levels of the vitamin was high 
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in both groups, especially in patients with MS, which 
indicates the vitamin D deficiency in most subjects. 
A significant decrease in serum levels of vitamin D in 
MS patients compared to healthy people can show the 
consistency of this study with previous studies on the role 
of vitamin D and MS. This study was in line with studies 
undertaken in other parts of the world on the role of 
vitamin D and MS. 
CONCLUSION 
Based on the above findings, it can be claimed that 
vitamin D deficiency and inadequate levels of vitamin D 
was present in most cases studied, i.e., both in healthy 
subjects and in patients with MS. This rate was lower in 
men, indicating inadequate intake of vitamin D in the 
community. Vitamin D deficiency, especially in patients 
with MS was higher. About the lower level of 25 (OH) D 
in patients in comparison to healthy people, it can be said 
that vitamin D has a protective effect against autoimmune 
disease, i.e., MS. But the relationship between the 
number of attacks per year and vitamin D3 level was not 
significant. However, it is suggested that further 
investigation to be done. Considering the above 
mentioned points, and the decrease of 25 (OH) D serum 
level in MS patients, it is recommended that patients to 
use vitamin supplements or have more exposure to sun. 
Funding: No funding sources 
Conflict of interest: None declared 
Ethical approval: The study was approved by the ethics 
committee of Ardabil University of Medical Science 
REFERENCES 
1. Pierrot-Deseilligny C. Clinical implications of a 
possible role of vitamin D in multiple sclerosis. J 
Neurol. 2009;256(9):1468-79. 
2. Smolders J, Damoiseaux J, Menheere P, Hupperts 
R. Vitamin D as an immune modulator in multiple 
sclerosis, a review. J Neuroimmunol. 
2008;194(1):7-17.  
3. Shahbeigi S, Pakdaman H, Mirzaeei N, Nikravesh 
E. Study serum 25-hydroxyvitamin D levels in MS 
patients and compare with control group. Iran J 
Neurol. 2008;7(24):70-4.  
4. Munger KL, Zhang S, O’reilly E, Hernan M, Olek 
M, Willett W, et al. Vitamin D intake and incidence 
of multiple sclerosis. Neurology. 2004;62(1):60-5. 
5. Hejazi E, Amani R, Sharafaldin Zadeh N, 
Cheraghian B. Comparison of the dietary intake of 
vitamin D and serum 25-OH-vitamin D3 levels 
between multiple sclerosis patients and healthy 
subjects. Iran J Nutr Sci Food Technol. 
2008;2(4):59-66. 
6. Ponsonby A-L, McMichael A, Van Der Mei I. 
Ultraviolet radiation and autoimmune disease: 
insights from epidemiological research. Toxicology. 
2002;181:71-8. 
7. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, 
Viljanen M, Hänninen A. 25-Hydroxyvitamin D 
levels in serum at the onset of multiple sclerosis. 
Multiple Sclerosis. 2005;11(3):266-71. 
8. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, 
Ardicoglu O, Özkan Y. Vitamin D deficiency and 
reduced bone mineral density in multiple sclerosis: 
effect of ambulatory status and functional capacity. 
J Bone Mineral Metab. 2005;23(4):309-13. 
9. Munger KL, Levin LI, Hollis BW, Howard NS, 
Ascherio A. Serum 25-hydroxyvitamin D levels and 
risk of multiple sclerosis. JAMA. 2006;296:2832-8. 
10. Samantha MK, Melanie RU, Paul O, Reinhold V. 
Safety of vitamin D3 in adults with multiple 
sclerosis. Am J Clin Nutr. 2007;86(3):645-51.      
11. Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson 
P, de Paz R, Souberbielle JC. Relationship between 
25-OH-D serum level and relapse rate in multiple 
sclerosis patients before and after vitamin D 
supplementation. Ther Adv Neurol Disord. 2012 
Jul;5(4):187-98. 
12. Sedrani SH. Low 25-hydroxyvitamin D and normal 
serum calcium concentrations in Saudi Arabia: 
Riyadh region. Ann Nutr Metab. 1984;28(3):181-5. 
13. Azizi F, Rais-Zadeh F, Mir Said Ghazi A. Vitamin 
D deficiency in a group of Tehran population. Res 
Med. 2000;4:291-303.   
 
 
 
 
 
Cite this article as: Fattahzadeh Ardalani Gh, 
Khosravi A, Mousavi-Ataeei A. Vitamin D3 serum 
level in patients with multiple sclerosis. Int J Adv 
Med 2015;2:393-6. 
